
RealRate

PHARMACEUTICAL 2018

Cryoport Inc. Rank 137 of 349







PHARMACEUTICAL 2018

Cryoport Inc. Rank 137 of 349



The relative strengths and weaknesses of Cryoport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cryoport Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 271% points. The greatest weakness of Cryoport Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is -109%, being 168% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	17,299
Cost of Goods Sold	5,988
Intangible Assets	91
Liabilities, Current	2,185
Liabilities, Non-Current	0
Other Assets	363
Other Compr. Net Income	0
Other Expenses	5,253
Other Liabilities	192
Other Net Income	14
Property and Equipment	2,511
Research and Development	1,206
Revenues	11,954
Selling, General and Administrative Expense	7,421

Output Variable	Value in 1000 USD
Assets	20,264
Liabilities	2,377
Expenses	19,868
Stockholders Equity	17,887
Net Income	-7,899
Comprehensive Net Income	-7,899
Economic Capital Ratio	-109%